Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Connective Tissue Research

METTL3-mediated m6A modification of ZIC2 promotes osteosarcoma development

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYan LiuXWXuan WangJYJianjun Yuan

Discussion

Loading...

Member takes

Overview

This study shows ZIC2 promotes tumor progression in osteosarcoma, indicating METTL3 as a key regulatory factor.

Key Points

  • ZIC2 promotes osteosarcoma development, enhancing tumor growth and invasion.
  • Quantitative analysis revealed ZIC2 and METTL3 expression is elevated in osteosarcoma tissues.
  • ZIC2 depletion resulted in reduced cell malignancy, supporting its role as a biomarker for osteosarcoma.
  • METTL3 facilitates ZIC2 mRNA stability through m6A modification, suggesting potential therapeutic targets.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68c241acb210217d647a0bb9https://doi.org/10.1080/03008207.2025.2540041
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The role of ZC3H13 in promoting M2 macrophage infiltration via m6A methylation in esophageal squamous cell carcinoma tumor progression2025
  2. 2Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m6A modification2025 · 1 citations
  3. 3METTL3: A dual regulator of oral tissue regeneration and malignancy with therapeutic implications for stem cell therapy and chemoresistance2025 · 1 citations
  4. 4METTL3-mediated m6A modification of DNMT1 enhances ovarian cancer progression2025
  5. 5387. RNA M6A METHYLATION PROMOTES TUMOR DEVELOPMENT AND WASF3 TRANSLATION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025